April 25th 2024
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
PSMA-Targeted Agent Identified Disease in Majority of Patients with Relapsed Prostate Cancer
February 12th 2021The potential to identify occult prostate cancer and accurately characterize disease burden was observed with the novel prostate specific membrane antigen (PSMA)–targeted radiopharmaceutical for PET imaging technique.
Redefining Prostate Cancer Care
February 11th 2021ONCOLOGY® sat down with Leonard G. Gomella, MD, professor and chair of Thomas Jefferson University Hospital’s Department of Urology and clinical director of the Sidney Kimmel Cancer Center Network, to discuss 10 years of breakthroughs for patients with prostate cancer and the hope that continued research will fully transform prostate cancer from a deadly disease into a chronic, manageable condition.
Capivasertib Plus Chemotherapy Leads to Better OS in mCRPC, Despite Missing Trials End Point
February 6th 2021A study of capivasertib plus chemotherapy did show a statistically significant extension in overall survival despite not reaching the primary end point of progression-free survival, suggesting a need for prospective validation studies to determine the reasoning behind the observed differences in these results.
Longer OS Observed for N1 Prostate Cancer Treated at Facilities with High Radiation Case Volume
February 1st 2021To evaluate the association between radiation facility case volume and OS among men with lymph node–positive prostate cancer who receive external beam radiation therapy, this cohort study assessed men diagnosed with T1N1M0 to T4N1M0 disease treated with curative-intent radiotherapy and androgen deprivation therapy.
Justin Gregg, MD, on the Use of the Mediterranean Diet in Men With Localized Prostate Cancer
January 19th 2021The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.
FDA Adds New Data to Label for Darolutamide in nmCRPC
January 8th 2021In response to the drug’s developer, the FDA added overall survival and other end point data to the label of darolutamide for its indication for treating patients with nonmetastatic castration-resistant prostate cancer who are receiving standard androgen-deprivation therapy.
Study Highlights Interchange Between Health Literacy and Shared Decision Making for PSA Screening
January 8th 2021“These findings highlight the dynamic interplay between both providers and their patients as well as between the latter’s [health literacy] and [shared decision making] that should inform the creation and promulgation of [shared decision making] guidelines, specifically when considering patients with low [health literacy],” wrote David-Dan Nguyen, MPH, and colleagues.
Olaparib Leads to Longer OS for BRCA1/2- or ATM–Altered mCRPC
December 31st 2020Treatment with olaparib versus physician’s choice of standard therapy led to a significantly longer duration of overall survival in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1/2 or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.
Increased Adiposity May Be Protective for Breast and Prostate Cancer in Certain Patients
December 20th 2020Though these collective findings demonstrate that genetic predisposition to increased weight is protective against breast and prostate cancer, further research is still necessary to work out exactly how this protection is provided, especially in breast cancer.
Role of Biomarkers in Selection of Patients with Prostate Cancer for Focal Therapy Currently Unclear
December 5th 2020A clear and reliable biomarker to select patients with prostate cancer for active surveillance or focal therapy has not yet been determined but inferring a course of action from existing biomarkers may be possible.
Reviewing Various Biomarker Settings for Patients with Prostate Cancer
December 4th 2020The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.